Pfizer to manufacture remdesivir for Gilead

By The Science Advisory Board staff writers

August 7, 2020 -- Pfizer has inked a multiyear agreement with Gilead Sciences to manufacture and supply Gilead's investigational antiviral drug remdesivir, joining other external manufacturing organizations in supporting efforts to scale up supply for the treatment of COVID-19.

Under the agreement, Pfizer will provide contract manufacturing services at its McPherson, KS, facility to manufacture and supply remdesivir for Gilead. This is part of the company's commitment to working with other pharmaceutical companies to address the COVID-19 crisis.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.